Press Releases

In This Section

Breadcrumb

Home // Investors // Press Releases //

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Novelion Therapeutics Reports Second Quarter 2018 Financial Results
Following recent marketing approval in both generalized and partial lipodystrophy indications, European launch of MYALEPTA® has commenced VANCOUVER, British Columbia , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing
View HTML
Toggle Summary Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
MYALEPTA is the first approved therapy in Europe indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy patients VANCOUVER, British Columbia , July 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.
View HTML
Toggle Summary Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
Chief Operating Officer Jeff Hackman Appointed as Interim Chief Executive Officer (CEO) VANCOUVER, British Columbia , July 03, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.  (NASDAQ:NVLN) today announced that Mark Corrigan , M.D. has been appointed as Executive Chair of the Board of
View HTML
Toggle Summary Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
Data Show Leptin Replacement Therapy Sustainably Decreased Weight Over Time in Patients with Low Baseline Leptin Levels Company plans to initiate Phase 2 proof of concept study in hypoleptinemic metabolic disorder (HMD) by year-end VANCOUVER, British Columbia , June 25, 2018 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
Europe represents potentially the largest market for metreleptin with expected authorization in both generalized and partial lipodystrophy VANCOUVER, British Columbia , June 01, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing
View HTML
Toggle Summary Novelion Therapeutics Reports First Quarter 2018 Financial Results
VANCOUVER, B.C. , May 10, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases ("Novelion" or the "Company"), today reported financial results for the first
View HTML
Toggle Summary Novelion Therapeutics Supports World Lipodystrophy Day
VANCOUVER, British Columbia , March 31, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today recognizes World Lipodystrophy Day.
View HTML
Toggle Summary Novelion Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Novelion reports 2017 total net revenues of $138.4 million , in line with previously stated guidance Plans underway to address capital structure and advance metreleptin development program VANCOUVER, British Columbia , March 15, 2018 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc.
View HTML
Toggle Summary Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
Novelion Therapeutics Subsidiary Enters into $20 Million Term Loan Agreement with Sarissa Capital and Broadfin Capital
View HTML
Toggle Summary Novelion Therapeutics Observes Rare Disease Day
Company Joins NORD, EURORDIS, CORD, The Global Genes Project and Others Worldwide in Supporting Awareness of Rare Diseases
View HTML